{
    "nct_id": "NCT03798626",
    "official_title": "Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma",
    "inclusion_criteria": "* Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.\n* Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1.\n\nFor Cohort A:\n\n- First line metastatic colorectal cancer.\n\nFor Cohort B:\n\n- Second line metastatic colorectal cancer that has progressed on prior chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin.\n\nFor Cohort C:\n\n- Second line metastatic gastroesophageal cancer that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet.\n\nFor Cohort D:\n\n- Second or third line metastatic renal cell carcinoma with a clear-cell component and has received one or two lines of treatment for metastatic disease that included an anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment.\n\nFor subjects starting from Part 1a in Cohorts A and B:\n\n* Serum hs-CRP at screening ≥ 10 mg/L.\n* Not requiring immediate initiation of anti-cancer therapy per investigator's best judgement.\n\nFor subjects starting from Part 2 in Cohort C:\n\n- Serum hs-CRP at screening ≥ 10 mg/L.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "For All Cohorts:\n\n* Currently receiving any of the prohibited medications or has contraindications as outlined in the protocol.\n* Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery).\n* Suspected or proven immunocompromised state, or infections (as defined in the protocol).\n* Conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents.\n* Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease.\n\nFor Cohort D:\n\n* Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.\n* Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib.\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": ""
}